---
title: "Johnson & Johnson Rises 1.3% as Investors Seek Stability"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296822154.md"
description: "Johnson & Johnson shares rose 1.3% to $273.31 as investors sought defensive stability amid tech stock weakness. The company reported strong Q2 results, with sales up 6.6% to $25.3 billion and adjusted earnings of $2.90 per share. Despite management raising its operating outlook, the stock trades at a premium, significantly above its GF Value estimate, reflecting market concerns over biosimilar competition and acquisition-related dilution."
datetime: "2026-08-24T19:18:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296822154.md)
  - [en](https://longbridge.com/en/news/296822154.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296822154.md)
generator: "portal-rs"
---

# Johnson & Johnson Rises 1.3% as Investors Seek Stability

Johnson & Johnson , the pharmaceutical and medical-technology powerhouse, gained approximately 1.2% to $273.31 Monday afternoon. Technology stocks were cracking. Johnson & Johnson was climbing. Investors wanted defensive earningsand they were willing to pay up for them.

The fundamentals gave buyers a reason. Second-quarter sales jumped 6.6% to $25.3 billion, while adjusted earnings hit $2.90 per share. Innovative Medicine delivered 6.8% operational growth. MedTech added 3.6%. Management lifted its operating outlook, although acquisition-related dilution later pressured reported profit guidance.

Here is the catch: safety looks expensive. At $273.31, the stock sits 41.91% above its GF Value estimate of $192.59 and trades at roughly 32 times earnings. Stelara is battling biosimilars. MedTech execution remains uneven. Recent deals will weigh on near-term profits. Johnson & Johnson offers stability, but the market is already charging a premium for it. The pipeline now needs to deliver.

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [Trinity Legacy Partners LLC Sells 4,917 Shares of Johnson & Johnson $JNJ](https://longbridge.com/en/news/296589986.md)
- [Johnson & Johnson $JNJ Position Reduced by Oppenheimer Asset Management Inc.](https://longbridge.com/en/news/296697035.md)
- [Mirae Asset Global Investments Co. Ltd. Grows Stake in Johnson & Johnson $JNJ](https://longbridge.com/en/news/296080198.md)
- [Vest Financial LLC Sells 103,567 Shares of Johnson & Johnson $JNJ](https://longbridge.com/en/news/296462162.md)
- [Johnson & Johnson Gets FDA Approval for Imaavy to Treat Warm Autoimmune Hemolytic Anemia](https://longbridge.com/en/news/296840164.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**